45
Participants
Start Date
July 1, 2025
Primary Completion Date
July 1, 2028
Study Completion Date
July 1, 2028
Orelabrutinib
orelabrutinib 150mg/day PO once daily
Rituximab (R)
rituximab 375 mg/m² IV on day 1, 8, 15, 22 in Cycle 1, then day 1/cycle
BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)
the reference doses are as follows (each center may adjust them as appropriate based on actual conditions): carmustine 300mg/m² IV d-1; etoposide 200mg/m² IV d-6-(-3); cytarabine 200mg/m² IV d-6-(-3); melphalan 140mg/m² IV d-2.
orelabrutinib maintenance
orelabrutinib 150mg/day PO once daily
RECRUITING
Ruijin Hospital, Shanghai
Fujian Medical University Union Hospital
OTHER
The First Affiliated Hospital of Anhui Medical University
OTHER
The Third Xiangya Hospital of Central South University
OTHER
First Affiliated Hospital of Wenzhou Medical University
OTHER
Qilu Hospital of Shandong University
OTHER
Huadong Hospital
OTHER
Ruijin Hospital
OTHER